Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics

Psychiatry and Clinical Neurosciences

Volumn 58, Issue 3, 2004, Pages 268-273

  Watanabe, Akira ^a,b   Shibata, Isao ^b   Kato, Tadafumi ^b  

^a Kujira Hospital   (Japan)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Attitude to health; Atypical antipsychotic agents; Personal satisfaction; Quality of life; Side effect

Indexed keywords

ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BROMPERIDOL; CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUDITORY HALLUCINATION; AWARENESS; COGNITIVE DEFECT; CONCENTRATION LOSS; CONSTIPATION; DAILY LIFE ACTIVITY; DEPRESSION; DROWSINESS; DRUG CHOICE; DYSURIA; FATIGUE; FEMALE; HUMAN; HYPERSALIVATION; IMPATIENCE; INSOMNIA; IRRITABILITY; LOUDNESS RECRUITMENT; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PATIENT SATISFACTION; PERSECUTORY DELUSION; QUALITY OF LIFE; QUESTIONNAIRE; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; THOUGHT DISORDER; TREMOR; WEIGHT GAIN; WORK; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 3042778508     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2004.01230.x     Document Type: Article

References (29)

1. Beasley Jr CM, Hamilton SH, Crawford AM et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychopharmacol. 1997; 7: 125-137.
2. Inada Y, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr. Res. 2002; 57: 227-238.
3. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SCR, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl Acad. Sci. USA 1999; 96: 13 432-13 437.
4. Purdon SE, Jones BD, Stip E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry 2000; 57: 249-258.
5. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr. Res. 2001; 418: 17-28.
6. Voruganti L, Cortese L, Owyeumi K et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr. Res. 2002; 57: 201-208.
7. McEvoy JP, Scheifler PL, Frances A. The Expert Consensus Guideline Series: treatment of schizophrenia 1999. J. Clin. Psychiatry 1999; 60 (Suppl. 11): 12-19.
8. Aoba A. Typical and atypical anti-psychotic drugs used for the treatment of schizophrenia. Seishin Shinkeigaku Zasshi 2001; 103: 523-531 (in Japanese).
9. Sainfort F, Becker M, Diamond R. Judgments of quality of life of individuals with severe mental disorders: patient self-report versus provider perspectives. Am. J. Psychiatry 1996; 153: 497-502.
10. Fitzgerald PB, Williams CL, Corteling N et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr. Scand. 2001; 103: 387-392.
11. Voruganti LN & Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr. Res. 2002; 56: 37-46.
12. Bigelow DA, Gareau MJ, Young DJ. A quality of life interview. Psychosoc. Rehab. J. 1990; 14: 94-98.
13. Ruggeri M. Patients' and relatives' satisfaction with psychiatric services: the state of the art of its measurement. Soc. Psychiatr. Epidemiol. 1994; 29: 212-227.
14. Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int. Clin. Psychopharmacol. 1995; 10 (Suppl. 3): 123-133.
15. Voruganti LN, Heslegrave RJ, Awad AG. Quality of life measurement during antipsychotic drug therapy of schizophrenia. J. Psychiatry Neurosci. 1997; 22: 267-274.
16. Gebhardt R. Investigation of the subjective well-being of psychotic patients under neuroleptic therapy. Pharmacopsychiatry 1972; 5: 295-300.
17. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp. Community Psychiatry 1990; 41: 892-897.
18. Naber D. Subjective experiences of schizophrenic patients treated with antipsychotic medication. Int. Clin. Psychopharmacol. 1998; 13 (Suppl. 1): S41-S45.
19. Tempier R & Pawliuk N. Influence of novel and conventional antipsychotic medication on subjective quality of life. J. Psychiatry Neurosci. 2001; 26: 131-136.
20. Ritsner M, Ponizovsky A, Endicott J et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur. Neuropsychopharmacol 2002; 12: 31-38.
21. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophr. Res. 2000; 43: 135-145.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC, 1994.
23. Inagaki A, Inada T, Fujii Y et al. Dose Equivalence of Psychotic Drugs. Seiwa, Tokyo, 1999 (in Japanese).
24. Tollefson GD, Beasley CM Jr, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 1997; 154: 457-465.
25. Calman KC. Quality of life in cancer patients: an hypothesis. J. Med. Ethics 1984; 10: 124-127.
26. Franz M, Meyer T, Reber T, Gallhofer B. The importance of social comparisons for high levels of subjective quality of life in chronic schizophrenic patients. Qual. Life Res. 2000; 9: 481-489.
27. Stahl SM. 'Awakening' from schizophrenia: intramolecular polypharmacy and the atypical antipsychotics. J. Clin. Psychiatry 1997; 58: 381-382.
28. Geddecs J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376.
29. Green MF, Marder SR, Glynn SM et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Psychiatry 2002; 51: 972-978.